ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
| Revenue (TTM) | $5.73B |
| Gross Profit (TTM) | $3.54B |
| EBITDA | $2.13B |
| Operating Margin | 34.80% |
| Return on Equity | 26.40% |
| Return on Assets | 14.80% |
| Revenue/Share (TTM) | $39.61 |
| Book Value | $42.29 |
| Price-to-Book | 5.66 |
| Price-to-Sales (TTM) | 5.77 |
| EV/Revenue | 5.8 |
| EV/EBITDA | 14.87 |
| Quarterly Earnings Growth (YoY) | 23.20% |
| Quarterly Revenue Growth (YoY) | 5.90% |
| Shares Outstanding | $140.66M |
| Float | $139.83M |
| % Insiders | 0.51% |
| % Institutions | 73.02% |
Volatility is currently expanding
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
I present 10 high-quality dividend growth stocks with strong total return potential, screened for robust fundamentals and attractive valuations as of November 2026. Key criteria include Investment Score ≥70, future return potential ≥12%, consistent 7%+ dividend growth, and payout ratios below 100%. Top picks such as RMD, NTES, and NVDA offer compelling upside, with future return estimates driven by EPS growth, yield, and potential valuation mean reversion.
ResMed reported that core constant currency revenue grew 7% in the first quarter. Patients on GLP-1 drugs are 11% more likely to start CPAP therapy.
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.
ResMed NYSE: RMD reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in life-support device sales. Non-GAAP diluted earnings per share rose 14% to $2.91.
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RMD and any ticker you trade — then tracks every position and per-strategy win rate.
